AI-generated summary
This review describes two light-based approaches to the brain: photobiomodulation (PBM), which uses red and near-infrared light, and optogenetics, which uses genetically engineered light-sensitive proteins controlled by visible light. The authors report that PBM is safe, noninvasive, and suited to long-term treatment, while noting that there are currently no human optogenetics trials. The review also states that visible light penetrates tissue poorly, so near-infrared PBM may reach deeper tissue when applied outside the head.
- Who or what was studied
- unclear
- Wavelengths
- 650, 450, 650 nm
- Limits stated in the abstract
- The abstract describes a review and states that there are currently no human trials of optogenetics on the human brain.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on psychiatryonline.org.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 650 nm, 100 nm, 450 nm
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Near-infrared, Low-level laser therapy, Cytochrome c oxidase, Wavelength. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.